Physician profile
Christopher Elliott
NPI 1700655214
$1,503.43
in general payments reported to CMS, 2019-2025
18 companies · $1,049 in 2025
The $1,049 reported for 2025 was more than what 81% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $454 · 2025: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,503.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $224.97 | 2024-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $171.52 | 2024-2025 | Caplyta |
| Tempus Ai, INC | $163.28 | 2024 | |
| Vanda Pharmaceuticals INC. | $159.05 | 2025 | Fanapt, Hetlioz |
| Abbvie INC. | $144.86 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $105.82 | 2025 | Invega Sustenna, Spravato |
| Axsome Therapeutics, INC. | $94.71 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $66.43 | 2024-2025 | Rexulti, Abilify Maintena |
| Bausch Health US, LLC | $61.35 | 2024-2025 | Aplenzin |
| Collegium Pharmaceutical, INC. | $50.33 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $49.24 | 2025 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $47.66 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $46.59 | 2024-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $39.77 | 2025 | Austedo Xr, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $25.05 | 2025 | Fruzaqla |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $22.47 | 2024 | Dyanavel Xr |
| Almatica Pharma LLC | $17.14 | 2025 | Loreev Xr |
| Tms Neurohealth Centers INC. | $13.19 | 2025 | Tms Neurohealth Centers INC. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Elliott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.